Biosynex focuses its development on products with high value added. Strategic choices will include both on niche markets and innovative new medical applications in the field of rapid diagnostic test (RDT).
By its desire to be a recognized innovator in the ToR , the Biosynex Group has implemented a policy of protection of proactive intellectual property.
Then, a first European patent ( EP2798144 ) was issued for his Biosynex break test of fetal membranes , based on the simultaneous detection of both markers ( AFP and IGFBP -1). The national patent applications for this invention are underway in Japan, Australia and Canada.
